KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Front Immunol. 2022 Mar 16;13:845969. doi: 10.3389/fimmu.2022.845969. eCollection 2022.
To control the coronavirus disease 2019 (COVID-19) pandemic and the emergence of different variants of concern (VoCs), novel vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed. In this study, we report the potent immunogenicity and efficacy induced in hamsters by a vaccine candidate based on a modified vaccinia virus Ankara (MVA) vector expressing a human codon optimized full-length SARS-CoV-2 spike (S) protein (MVA-S). Immunization with one or two doses of MVA-S elicited high titers of S- and receptor-binding domain (RBD)-binding IgG antibodies and neutralizing antibodies against parental SARS-CoV-2 and VoC alpha, beta, gamma, delta, and omicron. After SARS-CoV-2 challenge, MVA-S-vaccinated hamsters showed a significantly strong reduction of viral RNA and infectious virus in the lungs compared to the MVA-WT control group. Moreover, a marked reduction in lung histopathology was also observed in MVA-S-vaccinated hamsters. These results favor the use of MVA-S as a potential vaccine candidate for SARS-CoV-2 in clinical trials.
为了控制 2019 年冠状病毒病（COVID-19）大流行和不同关切变异株（VOCs）的出现，需要针对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的新型疫苗。在这项研究中，我们报告了基于改良安卡拉牛痘病毒（MVA）载体表达人密码子优化全长 SARS-CoV-2 刺突（S）蛋白（MVA-S）的疫苗候选物在仓鼠中诱导的强大免疫原性和功效。用一剂或两剂 MVA-S 免疫可引起针对亲本 SARS-CoV-2 和 VOC alpha、beta、gamma、delta 和 omicron 的 S 和受体结合域（RBD）结合 IgG 抗体和中和抗体的高滴度。在 SARS-CoV-2 攻毒后，与 MVA-WT 对照组相比，MVA-S 接种的仓鼠肺部的病毒 RNA 和传染性病毒明显减少。此外，在 MVA-S 接种的仓鼠中还观察到肺部组织病理学明显减少。这些结果支持将 MVA-S 用作 SARS-CoV-2 在临床试验中的潜在疫苗候选物。
